Dave is a life sciences industry veteran with an extensive track record of success across the life sciences industry of scaling and delivering value with therapeutic, diagnostic, and life science tools companies in both private and public settings. Most recently, he was president and chief executive officer of Omniome, where he guided and scaled the DNA sequencing company from the early technology development stage through the delivery of its beta prototype leading to its sale to PacBio in 2021. Prior to Omniome, Dave served as the president and chief operating officer of Ariosa Diagnostics, a global diagnostics company focused on using cell-free DNA in non-invasive prenatal testing that was acquired by Roche in 2014. Post-acquisition, Dave served as lifecycle leader, site head, and a core member of the Roche Sequencing Solutions leadership team. He has also held positions at Johnson & Johnson, Eli Lilly and Company, Valeant Pharmaceuticals, and Dow Pharmaceuticals Sciences.

Samuel joined ClearNote Health at its inception and has co-authored many of the research papers we have published about our epigenomics technology platform and our DNA-based 5-hydroxymethylcytosine (5hmC) biomarker. For more than 20 years, he has held leadership positions in genomics and molecular diagnostic development at companies including Celera, Genomic Health, Quanticel Pharmaceuticals (now part of Celgene), and Impact Genomics/Lexent Bio which he co-founded and is now a part of Foundation Medicine. Samuel has also served on the faculty at the J. Craig Venter Institute, Scripps Translational Science Institute and Scripps Research Institute. He holds degrees from the University of Bristol and the University of Leeds in the United Kingdom.

Wayne has more than 20 years of experience in bioinformatics, genomics and drug discovery. He cofounded Atreca and Innectus, and held leadership positions at Renovis (now part of Evotec), Ceres, and Incyte Pharmaceuticals. Wayne has been granted US patents and has co-authored multiple peer-reviewed publications. He holds degrees from Stanford University, Princeton University, and University of Minnesota.

Jeff is a physician-scientist and biotechnology executive with extensive experience in oncology drug and diagnostic development across both academic medicine and the life sciences industry. Most recently, he served as the global head of diagnostics for Eli Lilly. Prior to this he was the chief medical officer at GRAIL, where he led the medical and laboratory teams responsible for the development and clinical implementation of the company’s blood-based multi-cancer early detection test.

Earlier in his career, Jeff held multiple leadership roles across Roche, Genentech, and Foundation Medicine spanning research, clinical development, and medical affairs. As senior vice president and head of clinical development and medical affairs at Foundation Medicine, he led the development and launch of cancer genomic profiling solutions and contributed to multiple drug and companion diagnostic programs. Prior to entering industry, Jeff practiced medical oncology and led a research laboratory at the University of California, San Francisco.

Jeff completed oncology and cancer immunology training at Memorial Sloan Kettering Cancer Center and internal medicine training at The Johns Hopkins Hospital.

Anna has over a decade of experience in next-generation sequencing assay workflows and has worked as a senior scientist at ClearNote Health. Previously, at Genomic Health, she led the technical development of blood-based liquid biopsy assay. Anna holds a PhD in Molecular Oncology from the University of Oslo, Norway in collaboration with Stanford where she spent most of her time in the optimization of array CGH. She holds a Master’s in Medical Biotechnology from the University of Modena School of Medicine, Italy.

Eric has more than 20 years of experience directing IT for life sciences companies including Response Genetics Inc., Cypress Bioscience Inc., Suneva Medical Inc., and Orchestra Therapeutics Inc. He holds a B.S. in Business Administration/Information and Decision Systems from San Diego State University. He also served in the U.S. Marine Corps.

Shimul has served as a clinical laboratory director in multiple laboratories including Rady Children’s Institute for Genomic Medicine (RCIGM), Illumina Inc. and Quest Diagnostics. He has dedicated his career to implementing new genomic technologies to improve patient care and outcomes. He is a board-certified clinical molecular geneticist and licensed as a laboratory director in California, Florida and New York. He has authored over 30 peer-reviewed publications.

With a PhD from Vanderbilt, Gulfem has over a decade of experience in leveraging cancer epigenomics to drive advancements across drug discovery, translational research and biomarker development. Her prior commercial experience includes roles at Celgene and Genentech. Gulfemjoined ClearNote in 2018 and has been pivotal in developing the applications of the platform for pancreatic cancer early detection and treatment response. She is a passionate advocate for advancing precision medicine to better patient outcomes.

Jeremy leads brand strategy, go-to-market execution, provider engagement, and patient education initiatives. He brings deep experience building and scaling innovative healthcare technologies, with a strong track record of advancing commercialization and driving market adoption.

Prior to joining ClearNote Health, Jeremy served as Vice President of Marketing at iCAD, a global leader in AI-powered breast health solutions. Earlier in his career, he spent more than 16 years at Myriad Genetics in senior marketing leadership roles across imaging, oncology, and women’s health.

Jeremy holds a Bachelor of Science from The Pennsylvania State University and a Master of Science from the University of Utah.

Irene leads regulatory submissions, quality oversight, and cross-functional alignment to ensure the company’s platform meets the highest clinical and regulatory standards. Irene has more than 17 years of experience in global regulatory strategy, quality systems implementation, and compliance in complex diagnostic environments at leading diagnostics and pharmaceutical organizations, including Revvity, ChromaCode, Thermo Fisher Scientific, Shire, and Abbott.

Irene earned a bachelor of science degree from the University of California, San Diego, and a master of science degree from San Diego State University.

Daniel brings a successful history of scaling innovative diagnostics and biotech solutions from early-stage development to international market adoption. He oversees global go-to-market strategy, business development, partnership management, and market access initiatives to accelerate the commercial expansion of ClearNote Health's epigenetic-based early cancer detection portfolio. He has 20 years of experience in international commercial leadership across the biotech and medtech sectors, having held senior roles at Centogene and Roche Diagnostics, with increasing responsibility across global marketing, product management, and strategic partnerships.

Daniel earned a bachelor of science degree and a master of business administration degree from the Graduate School Rhein-Neckar in Mannheim, Germany, along with a doctor of business administration from Warsaw Management University in Warsaw, Poland.